Our analysis highlighted several potent drug targets for AD, including ABAT, ATP2B1, HEXB, CHRM5, KIF1A, GLUD1, KCNS1, RCVRN, and RIPK2. For example, GLUD1 is upregulated in AD-associated microglia, and its protein (UniProt ID: P00367; The UniProt Consortium, 2023) is elevated in the frontal cortex and hippocampus of the 5xFAD mouse model of AD (Savas et al., 2017). Here, ATP2B1 is linked to Alzheimer disease.